Bio Gene (Australia) Performance
| BGT Stock | 0.04 0 2.44% |
The firm shows a Beta (market volatility) of 0.39, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bio Gene's returns are expected to increase less than the market. However, during the bear market, the loss of holding Bio Gene is expected to be smaller as well. At this point, Bio Gene Technology has a negative expected return of -0.0938%. Please make sure to confirm Bio Gene's information ratio, total risk alpha, potential upside, as well as the relationship between the jensen alpha and treynor ratio , to decide if Bio Gene Technology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bio Gene Technology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Bio Gene is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
1 | BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - StockTitan | 10/11/2024 |
| Begin Period Cash Flow | 3 M |
Bio |
Bio Gene Relative Risk vs. Return Landscape
If you would invest 4.50 in Bio Gene Technology on September 12, 2024 and sell it today you would lose (0.50) from holding Bio Gene Technology or give up 11.11% of portfolio value over 90 days. Bio Gene Technology is producing return of less than zero assuming 4.2897% volatility of returns over the 90 days investment horizon. Simply put, 38% of all stocks have less volatile historical return distribution than Bio Gene, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Bio Gene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio Gene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bio Gene Technology, and traders can use it to determine the average amount a Bio Gene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0219
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BGT |
Estimated Market Risk
| 4.29 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bio Gene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bio Gene by adding Bio Gene to a well-diversified portfolio.
Bio Gene Fundamentals Growth
Bio Stock prices reflect investors' perceptions of the future prospects and financial health of Bio Gene, and Bio Gene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio Stock performance.
| Return On Equity | -0.8 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 6.05 M | |||
| Shares Outstanding | 201.36 M | |||
| Price To Book | 2.89 X | |||
| Price To Sales | 450.65 X | |||
| Revenue | 18.32 K | |||
| Gross Profit | 222.1 K | |||
| EBITDA | (2.97 M) | |||
| Net Income | (2.41 M) | |||
| Total Debt | 368.45 K | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (2.75 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 3.16 M | |||
| Retained Earnings | (19.64 M) | |||
About Bio Gene Performance
Assessing Bio Gene's fundamental ratios provides investors with valuable insights into Bio Gene's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Bio Gene is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Bio Gene is entity of Australia. It is traded as Stock on AU exchange.Things to note about Bio Gene Technology performance evaluation
Checking the ongoing alerts about Bio Gene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bio Gene Technology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bio Gene Technology generated a negative expected return over the last 90 days | |
| Bio Gene Technology has some characteristics of a very speculative penny stock | |
| Bio Gene Technology has high historical volatility and very poor performance | |
| Bio Gene Technology has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 18.32 K. Net Loss for the year was (2.41 M) with profit before overhead, payroll, taxes, and interest of 222.1 K. | |
| Bio Gene generates negative cash flow from operations | |
| About 43.0% of the company shares are held by company insiders |
- Analyzing Bio Gene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio Gene's stock is overvalued or undervalued compared to its peers.
- Examining Bio Gene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio Gene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio Gene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bio Gene's stock. These opinions can provide insight into Bio Gene's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Bio Stock Analysis
When running Bio Gene's price analysis, check to measure Bio Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Gene is operating at the current time. Most of Bio Gene's value examination focuses on studying past and present price action to predict the probability of Bio Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Gene's price. Additionally, you may evaluate how the addition of Bio Gene to your portfolios can decrease your overall portfolio volatility.